SEC Tracker
Get the app
Person · CIK 1772518

Elena Ridloff

CFO and CBO at Sionna Therapeutics; director at Immunic, Kymera Therapeutics and Kronos Bio

Earlier: Acadia Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$6.6M
Noticed on Form 144$3.9M
Bought on Form 4$50K
Companies5

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Sionna Therapeutics SIONCommon StockDirectly133,069Sep 17, 2026 · Filing · EDGAR
Sionna Therapeutics SIONNon-Qualified Stock Option (right to buy)
exercise $7.18, expires Jan 1, 2036, into Common Stock
Directly165,440Sep 17, 2026 · Filing · EDGAR
Immunic IMUXStock Option
exercise $14.54, expires Aug 6, 2036, into Common Stock
Directly50,740Aug 6, 2026 · Filing · EDGAR
Kymera Therapeutics KYMRStock Option (Right to Buy)
exercise $99.87, expires Jun 23, 2036, into Common Stock
Directly6,068Jun 24, 2026 · Filing · EDGAR
Acadia PharmaceuticalsCommon StockDirectly10,553Apr 30, 2021 · Filing · EDGAR
Acadia PharmaceuticalsRestricted Stock Units
into Common Stock
Directly6,491Apr 29, 2021 · Filing · EDGAR

Sold and noticed by quarter

Elena Ridloff: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2021 to Q4 2026$2M$0Q1 2021: notice not machine-readableQ1 2021: $158K sold on Form 4Q2 2021: notice not machine-readableQ2 2021: $21K sold on Form 4Q3 2021: $0 noticed on Form 144Q3 2021: $0 sold on Form 4Q4 2021: $0 noticed on Form 144Q4 2021: $0 sold on Form 4Q1 2022: $0 noticed on Form 144Q1 2022: $0 sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $0 noticed on Form 144Q4 2023: $0 sold on Form 4Q1 2024: $0 noticed on Form 144Q1 2024: $0 sold on Form 4Q2 2024: $0 noticed on Form 144Q2 2024: $0 sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $736K noticed on Form 144Q2 2025: $778K sold on Form 4Q3 2025: $1.9M noticed on Form 144Q3 2025: $2M sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $588K noticed on Form 144Q1 2026: $632K sold on Form 4Q2 2026: $641K noticed on Form 144Q2 2026: $654K sold on Form 4Q3 2026: $0 noticed on Form 144Q3 2026: $0 sold on Form 4Q4 2026: $0 noticed on Form 144Q4 2026: $0 sold on Form 4Q1 2021Q2 2022Q3 2023Q4 2024Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)Bought (Form 4)
Q2 2026$654K$641K—
Q1 2026$632K$588K—
Q3 2025$2M$1.9M—
Q2 2025$778K$736K—
Q2 2021$21KNot machine-readable—
Q1 2021$158KNot machine-readable—
Q4 2020——$50K
Q2 2020$559KNot machine-readable—
Q4 2019$1.8MNot machine-readable—

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Kymera Therapeutics KYMR · Morgan Stanley Smith Barney · 10b5-1 plan adopted Dec 11, 2025 · 3 notices
May 11, 20263,000 · ~$258KMay 11, 2026Sold as noticed Sold 3,000 at $87.00 on May 11 · $261K Form 4Filing · EDGAR
Apr 1, 20264,600 · ~$383KApr 1, 2026Sold as noticed Sold 4,600 in 2 sales, Apr 1 to Apr 1 · $393K Form 4Filing · EDGAR
Mar 31, 20267,400 · ~$588KMar 31, 2026Sold as noticed Sold 7,400 at $85.37 on Mar 31 · $632K Form 4Filing · EDGAR
Sionna Therapeutics SION · Morgan Stanley Smith Barney · 10b5-1 plan adopted May 20, 2025 · 3 notices
Aug 26, 202533,000 · ~$794KAug 26, 2025Sold as noticed Sold 33,000 in 5 sales, Aug 26 to Sep 2 · $842K Form 4 (1) · Form 4 (2)Filing · EDGAR
Aug 20, 202517,500 · ~$376KAug 20, 2025Sold as noticed Sold 17,500 at $22.69 on Aug 20 · $397K Form 4Filing · EDGAR
Aug 19, 202534,500 · ~$738KAug 19, 2025Sold as noticed Sold 34,500 at $21.08 on Aug 19 · $727K Form 4Filing · EDGAR
Kymera Therapeutics KYMR · Morgan Stanley Smith Barney · 10b5-1 plan adopted Nov 25, 2024 · 2 notices
Jun 11, 20254,500 · ~$219KJun 11, 2025Sold as noticed Sold 4,500 at $50.00 on Jun 11 · $225K Form 4Filing · EDGAR
Jun 3, 202512,000 · ~$518KJun 3, 2025Sold as noticed Sold 12,000 in 2 sales, Jun 3 to Jun 3 · $553K Form 4Filing · EDGAR
Sales without a matching Form 144 · 8 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Notice not machine-readable Acadia Pharmaceuticals: Sold 1,032 at $20.33 on Apr 30, 2021 · $21KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals: Sold 2,051 at $50.61 on Feb 4, 2021 · $104KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals: Sold 1,016 at $53.34 on Jan 6, 2021 · $54KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals: Sold 1,050 at $49.22 on Apr 30, 2020 · $52KFiling · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals: Sold 10,000 at $50.74 on Apr 29, 2020 · $507K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals: Sold 19,478 at $49.09 on Dec 9, 2019 · $956K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals: Sold 5,502 at $49.81 on Dec 9, 2019 · $274K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Acadia Pharmaceuticals: Sold 11,020 at $50.60 on Dec 9, 2019 · $558K (10b5-1 plan)Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Sionna Therapeutics SION CFO and CBO · filings 2025 to 2026 · sold $2M · $1.9M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Sep 17, 2026Grant or award from the company+47,26985,801 directFiling · EDGAR
Sep 17, 2026Grant or award from the company+47,268133,069 directFiling · EDGAR
Sep 17, 2026Grant or award from the company
Non-Qualified Stock Option (right to buy)
+165,440165,440 directFiling · EDGAR
Sep 17, 2026Returned to the company
Non-Qualified Stock Option (right to buy)
−165,4400 directFiling · EDGAR
Jan 2, 2026Grant or award from the company
Non-Qualified Stock Option (right to buy)
+165,440165,440 directFiling · EDGAR
Sep 2, 2025Sale under a 10b5-1 plan−8,836$25.08$222K38,532 directFiling · EDGAR
Aug 29, 2025Sale under a 10b5-1 plan−748$25.18$19K47,368 directFiling · EDGAR
Aug 28, 2025Sale under a 10b5-1 plan−16,098$25.97$418K48,116 directFiling · EDGAR
Aug 27, 2025Sale under a 10b5-1 plan−3,618$25.10$91K64,214 directFiling · EDGAR
Aug 26, 2025Sale under a 10b5-1 plan−3,700$25.13$93K67,832 directFiling · EDGAR
Aug 20, 2025Sale under a 10b5-1 plan−17,500$22.69$397K71,532 directFiling · EDGAR
Aug 19, 2025Sale under a 10b5-1 plan−34,500$21.08$727K89,032 directFiling · EDGAR
Feb 6, 2025Grant or award from the company
Stock Option (Right to Buy)
+157,820157,820 directFiling · EDGAR

Immunic IMUX Director · filings 2026 to 2026

DateTransactionSharesPriceValueHeld afterSource
Aug 6, 2026Grant or award from the company
Stock Option
+50,74050,740 directFiling · EDGAR

Kymera Therapeutics KYMR Director · filings 2021 to 2026 · sold $2.1M · $2M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Jun 24, 2026Grant or award from the company
Stock Option (Right to Buy)
+6,0686,068 directFiling · EDGAR
May 11, 2026Option or RSU exercised or converted+3,000$31.20$94K3,000 directFiling · EDGAR
May 11, 2026Sale under a 10b5-1 plan−3,000$87.00$261K0 directFiling · EDGAR
May 11, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−3,00013,000 directFiling · EDGAR
Apr 1, 2026Option or RSU exercised or converted+4,600$14.18$65K4,600 directFiling · EDGAR
Apr 1, 2026Sale under a 10b5-1 plan−3,400$85.19$290K1,200 directFiling · EDGAR
Apr 1, 2026Sale under a 10b5-1 plan−1,200$86.05$103K0 directFiling · EDGAR
Apr 1, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−4,6000 directFiling · EDGAR
Mar 31, 2026Option or RSU exercised or converted+7,400$14.18$105K7,400 directFiling · EDGAR
Mar 31, 2026Sale under a 10b5-1 plan−7,400$85.37$632K0 directFiling · EDGAR
Mar 31, 2026Option or RSU exercised or converted
Stock Option (Right to Buy)
−7,4004,600 directFiling · EDGAR
Jun 25, 2025Grant or award from the company
Stock Option (Right to Buy)
+16,00016,000 directFiling · EDGAR
Jun 11, 2025Option or RSU exercised or converted+4,500$20.29$91K4,500 directFiling · EDGAR
Jun 11, 2025Sale under a 10b5-1 plan−4,500$50.00$225K0 directFiling · EDGAR
Jun 11, 2025Option or RSU exercised or converted
Stock Option (Right to Buy)
−4,5004,500 directFiling · EDGAR
Jun 3, 2025Option or RSU exercised or converted+12,000$27.67$332K12,000 directFiling · EDGAR
Jun 3, 2025Sale under a 10b5-1 plan−7,200$45.50$328K4,800 directFiling · EDGAR
Jun 3, 2025Sale under a 10b5-1 plan−4,800$47.00$226K0 directFiling · EDGAR
Jun 3, 2025Option or RSU exercised or converted
Stock Option (Right to Buy)
−12,0000 directFiling · EDGAR
Jun 18, 2024Grant or award from the company
Stock Option (Right to Buy)
+16,00016,000 directFiling · EDGAR
Jun 15, 2023Grant or award from the company
Stock Option (Right to Buy)
+12,00012,000 directFiling · EDGAR
Jun 29, 2022Grant or award from the company
Stock Option (Right to Buy)
+9,0009,000 directFiling · EDGAR
Jun 15, 2022Grant or award from the company
Stock Option (Right to Buy)
+12,00012,000 directFiling · EDGAR
Jun 16, 2021Grant or award from the company
Stock Option (Right to Buy)
+10,45910,459 directFiling · EDGAR
Mar 12, 2021Grant or award from the company
Stock Option (Right to Buy)
+20,91920,919 directFiling · EDGAR

Kronos Bio KRON Director · filings 2020 to 2025 · bought $50K

DateTransactionSharesPriceValueHeld afterSource
Jun 20, 2025Tendered in a change of control−25,296$0.57$14K0 directFiling · EDGAR
Jun 20, 2025Returned to the company
Stock Option (Right to Buy)
−25,8790 directFiling · EDGAR
Jun 20, 2025Returned to the company
Stock Option (Right to Buy)
−26,8710 directFiling · EDGAR
Jun 20, 2025Returned to the company
Stock Option (Right to Buy)
−15,4500 directFiling · EDGAR
Jun 20, 2025Returned to the company
Stock Option (Right to Buy)
−34,0000 directFiling · EDGAR
Jun 20, 2025Returned to the company
Stock Option (Right to Buy)
−17,0000 directFiling · EDGAR
Jun 20, 2025Returned to the company
Stock Option (Right to Buy)
−17,0000 directFiling · EDGAR
Jun 25, 2024Grant or award from the company+11,33325,296 directFiling · EDGAR
Jun 25, 2024Grant or award from the company
Stock Option (Right to Buy)
+17,00017,000 directFiling · EDGAR
Jun 22, 2023Grant or award from the company+11,33313,963 directFiling · EDGAR
Jun 22, 2023Grant or award from the company
Stock Option (Right to Buy)
+17,00017,000 directFiling · EDGAR
Jun 22, 2022Grant or award from the company
Stock Option (Right to Buy)
+34,00034,000 directFiling · EDGAR
Jun 22, 2021Grant or award from the company
Stock Option (Right to Buy)
+15,45015,450 directFiling · EDGAR
Oct 14, 2020Open-market or private purchase+2,630$19.00$50K2,630 directFiling · EDGAR

Acadia Pharmaceuticals EVP and CFO · filings 2019 to 2021 · sold $2.5M

DateTransactionSharesPriceValueHeld afterSource
Apr 30, 2021Open-market or private sale−1,032$20.33$21K10,553 directFiling · EDGAR
Apr 29, 2021Option or RSU exercised or converted+3,24511,585 directFiling · EDGAR
Apr 29, 2021Option or RSU exercised or converted
Restricted Stock Units
−3,2456,491 directFiling · EDGAR
Feb 23, 2021Grant or award from the company
Stock Options (Right to Buy)
+36,23136,231 directFiling · EDGAR
Feb 23, 2021Grant or award from the company
Restricted Stock Units
+9,8399,839 directFiling · EDGAR
Feb 4, 2021Grant or award from the company+6,49010,391 directFiling · EDGAR
Feb 4, 2021Open-market or private sale−2,051$50.61$104K8,340 directFiling · EDGAR
Jan 6, 2021Option or RSU exercised or converted+2,7224,917 directFiling · EDGAR
Jan 6, 2021Open-market or private sale−1,016$53.34$54K3,901 directFiling · EDGAR
Jan 6, 2021Option or RSU exercised or converted
Restricted Stock Units
−1,0169,873 directFiling · EDGAR
Apr 30, 2020Open-market or private sale−1,050$49.22$52K2,195 directFiling · EDGAR
Apr 29, 2020Option or RSU exercised or converted+10,000$25.12$251K10,000 directFiling · EDGAR
Apr 29, 2020Sale under a 10b5-1 plan−10,000$50.74$507K0 directFiling · EDGAR
Apr 29, 2020Option or RSU exercised or converted+3,2453,245 directFiling · EDGAR
Apr 29, 2020Option or RSU exercised or converted
Stock Option (Right to Buy)
−10,00035,547 directFiling · EDGAR
Apr 29, 2020Option or RSU exercised or converted
Restricted Stock Units
−3,2459,736 directFiling · EDGAR
Jan 6, 2020Grant or award from the company
Stock Options (Right to Buy)
+39,51639,516 directFiling · EDGAR
Jan 6, 2020Grant or award from the company
Restricted Stock Units
+10,88910,889 directFiling · EDGAR
Dec 9, 2019Option or RSU exercised or converted+36,000$15.81$569K36,000 directFiling · EDGAR
Dec 9, 2019Sale under a 10b5-1 plan−11,020$50.60$558K24,980 directFiling · EDGAR
Dec 9, 2019Sale under a 10b5-1 plan−5,502$49.81$274K19,478 directFiling · EDGAR
Dec 9, 2019Sale under a 10b5-1 plan−19,478$49.09$956K0 directFiling · EDGAR
Dec 9, 2019Option or RSU exercised or converted
Stock Option (Right to Buy)
−36,00064,000 directFiling · EDGAR
Apr 29, 2019Grant or award from the company
Stock Options (Right to Buy)
+45,54745,547 directFiling · EDGAR
Apr 29, 2019Grant or award from the company
Restricted Stock Units
+12,98112,981 directFiling · EDGAR
Apr 1, 2019Grant or award from the company
Restricted Stock Units
+40,00040,000 directFiling · EDGAR
All 49 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Sep 18, 2026Form 4Sionna Therapeutics SIONFiling · EDGAR
Aug 10, 2026Form 4Immunic IMUXFiling · EDGAR
Aug 10, 2026Form 3Immunic IMUXFiling · EDGAR
Jun 25, 2026Form 4Kymera Therapeutics KYMRFiling · EDGAR
May 11, 2026Form 144Kymera Therapeutics KYMRFiling · EDGAR
May 11, 2026Form 4Kymera Therapeutics KYMRFiling · EDGAR
Apr 1, 2026Form 144Kymera Therapeutics KYMRFiling · EDGAR
Apr 1, 2026Form 4Kymera Therapeutics KYMRFiling · EDGAR
Mar 31, 2026Form 144Kymera Therapeutics KYMRFiling · EDGAR
Jan 6, 2026Form 4Sionna Therapeutics SIONFiling · EDGAR
Sep 3, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Aug 28, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Aug 26, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Aug 21, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Aug 20, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Aug 19, 2025Form 144Sionna Therapeutics SIONFiling · EDGAR
Jun 26, 2025Form 4Kymera Therapeutics KYMRFiling · EDGAR
Jun 20, 2025Form 4Kronos Bio KRONFiling · EDGAR
Jun 11, 2025Form 144Kymera Therapeutics KYMRFiling · EDGAR
Jun 11, 2025Form 4Kymera Therapeutics KYMRFiling · EDGAR
Jun 3, 2025Form 144Kymera Therapeutics KYMRFiling · EDGAR
Jun 3, 2025Form 4Kymera Therapeutics KYMRFiling · EDGAR
Feb 10, 2025Form 4Sionna Therapeutics SIONFiling · EDGAR
Feb 6, 2025Form 3Sionna Therapeutics SIONFiling · EDGAR
Jun 26, 2024Form 4Kronos Bio KRONFiling · EDGAR
Jun 20, 2024Form 4Kymera Therapeutics KYMRFiling · EDGAR
Jun 26, 2023Form 4Kronos Bio KRONFiling · EDGAR
Jun 20, 2023Form 4Kymera Therapeutics KYMRFiling · EDGAR
Jul 1, 2022Form 4Kymera Therapeutics KYMRFiling · EDGAR
Jun 29, 2022Form 4Kronos Bio KRONFiling · EDGAR
Jun 16, 2022Form 4Kymera Therapeutics KYMRFiling · EDGAR
Apr 15, 2022Form 4/AKymera Therapeutics KYMRFiling · EDGAR
Apr 15, 2022Form 4/AKymera Therapeutics KYMRFiling · EDGAR
Jun 23, 2021Form 4Kronos Bio KRONFiling · EDGAR
Jun 17, 2021Form 4Kymera Therapeutics KYMRFiling · EDGAR
Apr 30, 2021Form 4Acadia PharmaceuticalsFiling · EDGAR
Mar 16, 2021Form 4Kymera Therapeutics KYMRFiling · EDGAR
Mar 16, 2021Form 3Kymera Therapeutics KYMRFiling · EDGAR
Feb 25, 2021Form 4Acadia PharmaceuticalsFiling · EDGAR
Feb 8, 2021Form 4Acadia PharmaceuticalsFiling · EDGAR
Jan 8, 2021Form 4Acadia PharmaceuticalsFiling · EDGAR
Oct 16, 2020Form 4Kronos Bio KRONFiling · EDGAR
Oct 8, 2020Form 3Kronos Bio KRONFiling · EDGAR
May 1, 2020Form 4Acadia PharmaceuticalsFiling · EDGAR
Jan 8, 2020Form 4Acadia PharmaceuticalsFiling · EDGAR
Dec 11, 2019Form 4Acadia PharmaceuticalsFiling · EDGAR
May 1, 2019Form 4Acadia PharmaceuticalsFiling · EDGAR
Apr 2, 2019Form 4Acadia PharmaceuticalsFiling · EDGAR
Apr 2, 2019Form 3Acadia PharmaceuticalsFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.